Featured Press Releases

Avanzanite Bioscience has appointed a new Chief Financial Officer

Avanzanite Bioscience has appointed a new Chief Financial Officer

BerGenBio selects 2nd dose in Phase 2a STK11m Non-Small Cell Lung Cancer trial.

BerGenBio selects 2nd dose in Phase 2a STK11m Non-Small Cell Lung Cancer trial.

  • 29 Jul 2024

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL...

Avenacy announces launch of Eptifibatide for Injection in the U.S.

Avenacy announces launch of Eptifibatide for Injection in the U.S.

Stay Protected

Stay Protected

Delcath Systems Receives FDA Clearance for IND Application to Begin Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems Receives FDA Clearance for IND Application to Begin Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Genmab: Epcoritamab combo shows high response in R/R DLBCL patients eligible for ASCT

Genmab: Epcoritamab combo shows high response in R/R DLBCL patients eligible for ASCT

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

  • Spruce Biosciences, Inc.
  • 18 Aug 2025
Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

  • SystImmune, Inc.
  • 18 Aug 2025
New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

  • Genexa
  • 15 Aug 2025
Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

  • Daewoong Therapeutics Inc
  • 13 Aug 2025
Abcentra LLC Commences Phase 2b

Abcentra LLC Commences Phase 2b 'FORTIFY' Trial with First Patient Dosed, Evaluating Orticumab for Cardiovascular Disease

  • Abcentra
  • 12 Aug 2025
Viatris announces the approval of the first generic iron sucrose injection in the U.S

Viatris announces the approval of the first generic iron sucrose injection in the U.S

  • Viatris Inc.
  • 11 Aug 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
August   2025
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.